- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | Bone Biologics Corp - 10-K, Annual Report | - | SEC Filings | ||
| 13.12.24 | Bone Biologics Corp - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Bone Biologics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10.24 | Bone Biologics Corp - 8-K, Current Report | - | SEC Filings | ||
| BONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 01.08.24 | Pre-market Movers: Bone Biologics, Immuneering, ALX Oncology, CareDx, MediaAlpha | 690 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.40 A.M. ET).In the Green Bone Biologics Corporation (BBLG) is up over 61%... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,111 | -5,27 % | Sernova Biotherapeutics Inc: Sernova to continue to Cohort C T1D trial in H2 2025 | ||
| ATOSSA THERAPEUTICS | 0,623 | -2,20 % | Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst | ||
| PING AN HEALTHCARE | 0,848 | -1,67 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports First Full-Year Profit in 2024 | Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success
SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,014 | -20,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,302 | -10,12 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,914 | -1,40 % | Cytosorbents Corp: CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 2024 marked by strong commercial execution and improved operating leverage
Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and... ► Artikel lesen | |
| VERU | 0,541 | -6,56 % | Veru Aktie: Kreuzung ohne klare Richtung! | Die Veru-Aktie konnte im jüngsten Handel einen leichten Aufschwung verzeichnen. Am 22. März stieg der Kurs um 2,35% auf 0,48 EUR, was eine positive Entwicklung gegenüber dem Vortagsschluss darstellt.... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,656 | -5,75 % | Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update | • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement... ► Artikel lesen | |
| VOLITIONRX | 0,560 | 0,00 % | VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx... ► Artikel lesen | |
| EKSO BIONICS | 0,381 | -2,81 % | Ekso Bionics Holdings Aktie: Beeindruckende Innovationskraft | Der Exoskelett-Hersteller verzeichnet im letzten Quartal 2024 Umsatzsteigerungen und Margenwachstum, kämpft jedoch mit Jahresrückgang bei hoher Aktienvolatilität. Ekso Bionics meldete für das vierte... ► Artikel lesen | |
| IMUNON | 0,940 | -2,08 % | Imunon, Inc.: IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer | First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3... ► Artikel lesen | |
| BEYOND AIR | 0,238 | +2,59 % | Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site | ||
| AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| AROVELLA THERAPEUTICS | 0,040 | -9,20 % | AROVELLA THERAPEUTICS LIMITED: Cancel - Proposed issue of securities - ALA | ||
| NOVACYT | 0,478 | +1,92 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights |
Das Unternehmen BONE BIOLOGICS CORP kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,844 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BONE BIOLOGICS CORP finden Sie auf Wallstreet Online.
